US Patent Issued to Dana-Farber Cancer Institute on Nov. 25 for "Compositions and methods for identification assessment, prevention, and treatment of Ewing sarcoma using TP53 dependency biomarkers and modulators" (Massachusetts Inventor)

ALEXANDRIA, Va., Nov. 25 -- United States Patent no. 12,480,163, issued on Nov. 25, was assigned to Dana-Farber Cancer Institute Inc. (Boston).

"Compositions and methods for identification assessment, prevention, and treatment of Ewing sarcoma using TP53 dependency biomarkers and modulators" was invented by Kimberly Stegmaier (Jamaica Plain, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention is based, in part, on the identification of TP53 dependency biomarkers, including MDM2, MDM4, USP7, and Wip1/PPM1D, as well as modulators and methods of use thereof, for identifying, assessing, preventing, and treating Ewing sarcoma."

The patent was filed on July 17, 2019, under Application No. 1...